Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Prinzmetal angina. Questions of pathogenesis, clinic, diagnosis and treatment].

Terapevticheskii arkhiv·2020
Same author

[Innovative methods-of treatment of cardiac patients in amultidisciplinary hospital].

Voenno-meditsinskii zhurnal·2018
Same author

[A case of adenovirus infection complicated by gram-negative polymicrobial sepsis: A clinical and morphological observation].

Terapevticheskii arkhiv·2016
Same author

[Myocardial infarction in young population].

Voenno-meditsinskii zhurnal·2015
Same author

[Bilateral massive pulmonary embolism: clinical observation and literature review].

Voenno-meditsinskii zhurnal·2015
Same author

[C-peptide and its role as a predicator of the cardiovascular complications].

Voenno-meditsinskii zhurnal·2014

Related Experiment Video

Updated: Jul 9, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
08:53

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

[Erythropoietin in clinical practice].

V I Baksheev, N M Kolomoets

    Klinicheskaia Meditsina
    |November 28, 2007
    PubMed
    Summary

    Erythropoietin (EP) is a protective cytokine with broad tissue effects. Recombinant EP (REP) and its analogs show promise for treating various diseases, warranting further clinical research and development.

    Area of Science:

    • Biochemistry
    • Molecular Biology
    • Immunology

    Context:

    • Erythropoietin (EP) is recognized as a pleiotropic tissue-protective cytokine.
    • EP receptors are widely distributed across various tissues.
    • EP exhibits anti-inflammatory, pro-angiogenic, and anti-apoptotic properties.

    Purpose:

    • To review the current understanding of erythropoietin (EP) and its therapeutic potential.
    • To explore the clinical applications of recombinant EP (REP) and EP analogs.
    • To highlight the need for continued clinical studies and development of novel EP analogs.

    Summary:

    • Erythropoietin (EP) demonstrates universal tissue-protective capabilities due to its pleiotropic effects.
    • Recombinant EP (REP) and analogs without erythropoietic activity are being investigated for diverse clinical applications, including neurology, cardiology, hematology, and oncology.

    More Related Videos

    Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
    14:22

    Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

    Published on: July 16, 2011

    Related Experiment Videos

    Last Updated: Jul 9, 2026

    A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
    08:53

    A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

    Published on: January 10, 2025

    Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
    14:22

    Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells

    Published on: July 16, 2011

  • The review emphasizes the ongoing research into EP's therapeutic possibilities and the necessity for developing new analogs with targeted actions.

    • Impact:

    • EP's multifaceted biological activities suggest significant therapeutic potential beyond its traditional role in hematology.
    • The development of REP and EP analogs offers promising avenues for treating a wide range of diseases.
    • Further clinical investigation and the creation of selective EP analogs are crucial for realizing its full clinical utility.